AN2 Therapeutics, Inc.

Healthcare

NASDAQ:ANTX · NASDAQ Global Select

Market Cap $137.01M Beta -0.98 P/E (TTM) -4.9

$5.00 +0.82%

+$0.04 today

52W Low $1.00High $6.91

Vol 0.48M · Avg 0.29M

EPS (TTM) -$1.01Biotechnology

Filings

Ground the analysis in primary documents

Pair price history with recent company filings so you can connect market moves to the actual disclosures behind the business.

Price History

Dividend-adjusted closing price

Events

Change

+367.29%

Period High

$5.46

Period Low

$1.03

Latest

$5.00

SEC Filings

Recent regulatory filings

No filings found.

Competitors

Peer companies in the same sector

Health

Q32 Bio Inc.

NASDAQ:QTTB

$163.15M

Verrica Pharmaceuticals Inc.

NASDAQ:VRCA

$61.89M

SAB Biotherapeutics, Inc.

SABS

$37.95M

Boundless Bio, Inc.

BOLD

$31.91M

iBio, Inc.

IBIO

$26.05M

Pluri Inc.

PLUR

$19.38M

Plus Therapeutics, Inc.

PSTV

$10.23M

Intensity Therapeutics, Inc.

INTS

$7.04M

NextCure, Inc.

NXTC

$5.47M

Iterum Therapeutics plc

ITRM

$1.60M

What is the latest ANTX filing?

The latest filing shown is 8-K dated Jun 9, 2026.

How many recent filings does ANTX have?

Intrinsic Alpha currently shows 20 recent filings for ANTX.

Explore More

Continue the stock analysis

Jump to another research area for this company.

OverviewStart with valuation, alerts, peers, and the full company snapshot.DCFAdjust assumptions and compare intrinsic value against the market price.FinancialsReview income statement, balance sheet, and cash flow trends.HealthCheck liquidity, leverage, and balance sheet strength.GrowthCompare historical growth, cash generation, targets, and peers.DividendsInspect dividend history, payout durability, and shareholder returns.ManagementReview leadership context, insider activity, and capital efficiency.